Tirzepatide and Hair Loss: What the Research Shows

*This article is for informational purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before starting any medication or making changes to your treatment plan.*

---

More hair than usual in the shower drain. A brush filling faster. A ponytail that feels thinner. You started tirzepatide a few months ago, the results are showing, and now your hair is doing something unexpected.

Hair loss is one of the most emotionally charged side effects a person can experience, even when treatment is working exactly as intended. It is also one of the most searched questions among people on GLP-1 medications. Here is a clear look at what the data actually shows, why it happens, and what tends to help.

---

Does Tirzepatide Cause Hair Loss?

Yes, hair loss is a documented adverse reaction in tirzepatide clinical trials. The FDA-approved prescribing information for Zepbound (tirzepatide for chronic weight management) lists hair loss among the most common adverse reactions reported in at least 5% of patients.

Across the pooled SURMOUNT-1 and SURMOUNT-2 trials, hair loss was reported in:

• 5% of patients on tirzepatide 5 mg, compared to 1% on placebo
• 4% on tirzepatide 10 mg, compared to 1% on placebo
• 5% on tirzepatide 15 mg, compared to 1% on placebo

Women were significantly more affected than men. Among women on tirzepatide, 7.1% reported hair loss, versus 1.3% of women on placebo. Among men, the rate was 0.5% on tirzepatide versus 0% on placebo.

Notably, no tirzepatide-treated patients in these trials discontinued treatment because of hair loss. [1]

For comparison, hair loss was reported in 2.5% of participants on semaglutide in the STEP 1 trial, versus 0.3% on placebo. [2] Tirzepatide's higher rates are consistent with its greater magnitude of weight loss, which appears to be the primary driver of the effect.

---

Why Does Hair Loss Happen on Tirzepatide?

Telogen Effluvium: The Most Likely Mechanism

Your hair grows in cycles. Most follicles are in the anagen (active growth) phase at any given time. A smaller proportion are in the telogen (resting) phase, after which the hair naturally sheds. The typical daily loss is 50 to 100 hairs.

When the body experiences significant physiological stress, including rapid weight loss, surgery, illness, or major nutritional change, it can trigger a condition called telogen effluvium. In this condition, an unusually large proportion of follicles shift prematurely into the resting phase. The result is a surge of shedding, typically appearing two to four months after the triggering event. [3]

The timing matters. If you started tirzepatide, began losing weight quickly, and noticed hair changes several months later, that lag is exactly consistent with telogen effluvium. The shedding you see now reflects the physiological change that happened earlier.

Critically, telogen effluvium does not damage follicles. The hair grows back.

Tirzepatide's Weight Loss Advantage May Explain Higher Rates

Tirzepatide produces greater average weight loss than semaglutide: approximately 22.5% body weight reduction at the highest dose in SURMOUNT-1, compared to roughly 15% with semaglutide in STEP 1. [1, 2]

More weight lost in less time means more physiological signal to the hair follicle cycle. A 2026 systematic review published in *Science Progress* found that tirzepatide, associated with the greatest weight loss magnitude among GLP-1 receptor agonists, was also most frequently linked to telogen effluvium. [4]

The FDA prescribing information for Zepbound explicitly states: "Hair loss adverse reactions in ZEPBOUND-treated patients were associated with weight reduction." The drug itself is not likely destroying follicles. The body is redistributing resources in response to rapid caloric deficit and weight change.

Nutritional Deficiencies as a Compounding Factor

GLP-1 receptor agonists suppress appetite and slow gastric emptying. When food intake decreases substantially, there is meaningful risk of falling short on nutrients that hair follicles depend on.

The nutrients most associated with hair loss during caloric restriction are:

• Protein: Hair is composed primarily of keratin, a structural protein. Inadequate protein intake during rapid weight loss is consistently linked to increased shedding. Most people need at least 1.2 to 1.6 grams of protein per kilogram of body weight during active weight loss to preserve lean mass and support hair health. [5]
• Iron: Iron deficiency, particularly low ferritin (stored iron), is a well-established cause of telogen effluvium. Women are especially susceptible.
• Zinc: Zinc supports protein synthesis and cell division, both relevant to follicle function. Dietary zinc often declines when total food intake drops significantly.
• Biotin: Deficiency is rare but possible with severely restricted eating.

A real-world cross-sectional analysis of 254 GLP-1 receptor agonist users found that Mounjaro (tirzepatide) users had significantly higher odds of experiencing hair loss compared to users of other GLP-1 medications (adjusted odds ratio 3.02, p = 0.009). Women and those with more prolonged use showed stronger associations. [6]

---

Who Is Most Affected?

The data consistently points to women as disproportionately affected. In the SURMOUNT trials, female tirzepatide users reported hair loss at 7.1% versus 1.3% for women on placebo. Male rates were far lower.

This pattern is not surprising. Telogen effluvium following rapid weight loss is more common in women generally, and women with pre-existing low ferritin levels (a common finding among menstruating women) are particularly vulnerable to shedding after physiological stress.

---

How Long Does Hair Loss on Tirzepatide Last?

For most people, the heaviest shedding follows peak weight loss velocity. As you move from rapid active loss into a slower, more stable phase, the physiological stress signal to the follicle cycle decreases.

Visible regrowth typically begins within three to six months of the shedding peak. Full volume restoration may take six to twelve months depending on individual hair growth rate (roughly half an inch per month on average).

The key variable is whether nutritional deficiencies are extending the shed phase. If protein or iron levels are low, shedding can persist beyond the initial telogen effluvium window. Correcting those deficiencies shortens recovery.

---

What You Can Do

Prioritize Protein

This is the single highest-impact lever for most people. Aim for at least 100 to 130 grams of protein daily during active weight loss, or discuss a personalized protein target with your provider based on your body weight and program goals.

Prioritize complete protein sources: eggs, Greek yogurt, cottage cheese, chicken, fish, lean beef, and legumes. If appetite suppression makes hitting protein targets difficult, a high-quality protein supplement can bridge the gap.

Check Your Labs

Ask your provider to run iron studies including ferritin, zinc, and a complete blood count. Identifying a specific deficiency gives you a targeted solution rather than guesswork. Low ferritin is especially worth investigating in women who menstruate, as even borderline-low iron stores can worsen and prolong shedding.

Be Thoughtful About Biotin Supplementation

Biotin is widely marketed for hair loss and is generally safe at moderate doses. However, high-dose biotin supplementation interferes with certain lab tests, including thyroid function tests and cardiac troponin assays. If you are taking biotin, tell your provider before any blood work.

Reduce Mechanical Stress

During active shedding, minimize additional hair damage. Avoid tight hairstyles, excessive heat styling, and harsh chemical treatments. Use a wide-tooth comb and shampoo gently. These steps do not address the underlying cause but reduce unnecessary additional shedding while recovery is underway.

Consider a Dermatology Referral

If hair loss is severe, persists beyond six months, involves visible patchy loss or scalp symptoms like itching or burning, a board-certified dermatologist can confirm the diagnosis and recommend targeted treatment if appropriate.

---

When to Talk to Your Provider

Contact your prescribing provider if:

• Hair loss is significant enough to cause visible thinning, not just increased shedding
• You have been on treatment for more than six months and hair loss is not improving
• You are concerned about nutritional deficiencies that have not been evaluated
• You are considering stopping your medication because of hair loss

Stopping a GLP-1 medication without a plan is rarely the better option for hair alone. Weight regain after discontinuation can itself trigger another round of telogen effluvium. The right conversation is with your provider, who can weigh the side effect against the health benefits of continuing treatment.

---

The Bottom Line

Hair loss on tirzepatide is real, it is recognized in the clinical data, and it is understandably upsetting. But the evidence consistently points toward a temporary, reversible mechanism: telogen effluvium driven by the body's response to rapid weight loss, compounded in many cases by insufficient protein or micronutrient intake.

The FDA prescribing information makes the connection explicit: hair loss in tirzepatide patients is associated with weight reduction, not a direct pharmacological effect on follicles. Tirzepatide's superior efficacy, the feature that makes it one of the most effective tools available for weight management, also makes the hair loss pattern more common than with lower-efficacy GLP-1 medications.

With the right nutritional support, targeted lab evaluation, and time, most people see full recovery. Do not stop treatment impulsively. Tell your provider. Fix your protein intake. And know that this is a recognized, manageable part of the tirzepatide experience for some people, one that resolves with the right approach.

---

*Curious whether tirzepatide is right for you? Check your eligibility for a medically supervised program through Prescriva and connect with a licensed provider who can support your complete treatment journey.*

---

Disclaimer: Compounded tirzepatide is not FDA-approved and has not been reviewed for safety, efficacy, or quality by the FDA. Compounded medications are not the same as, equivalent to, or interchangeable with FDA-approved branded medications. Individual results vary and are not guaranteed. Blue Oak Services LLC dba Prescriva is a management services organization (MSO) and does not practice medicine or make clinical decisions; all care is delivered by independently licensed healthcare providers. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Prescriva has no affiliation with Eli Lilly and Company.

---

Sources

1. Zepbound (tirzepatide) Prescribing Information. Eli Lilly and Company; 2023. Available from the U.S. FDA. Table 1: Adverse Reactions (≥2% and Greater than Placebo) in ZEPBOUND-Treated Adults.

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. *New England Journal of Medicine*. 2021;384(11):989-1002. PMID: 33567185. [https://doi.org/10.1056/NEJMoa2032183](https://doi.org/10.1056/NEJMoa2032183)

1. Grover C, Khurana A. Telogen effluvium. *Indian Journal of Dermatology, Venereology and Leprology*. 2013;79(5):591-603. PMID: 23974582. [https://doi.org/10.4103/0378-6323.116731](https://doi.org/10.4103/0378-6323.116731)

1. Gupta AK, Teasell EM, Economopoulos V, Mirmirani P. GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. *Science Progress*. 2026;109(2):368504261444578. PMID: 41998799. [https://doi.org/10.1177/00368504261444578](https://doi.org/10.1177/00368504261444578)

1. Stokes T, Hector AJ, Morton RW, McGlory C, Phillips SM. Recent perspectives regarding the role of dietary protein for the promotion of muscle hypertrophy with resistance exercise training. *Nutrients*. 2018;10(2):180. PMID: 29414855. [https://doi.org/10.3390/nu10020180](https://doi.org/10.3390/nu10020180)

1. Argobi Y, Jadaan NS, Alshalhoob HB, et al. Predictors and characteristics of hair loss among users of GLP-1 receptor agonists: A cross-sectional analysis. *Journal of Cosmetic Dermatology*. 2026;25(4):e70835. PMID: 41914454. [https://doi.org/10.1111/jocd.70835](https://doi.org/10.1111/jocd.70835)